Clinical Trials
Clinical Trials
Clinical Trials
Join the Fight against Alzheimer’s
ALTER-AD
The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, activities of daily living, resource utilisation, safety and tolerability, in subjects with mild to moderately severe probable AD. This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants. If you have any questions about our investigational product candidates and/or our ongoing clinical trialsReach Out to Find Out More